Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

MKSAP: 58-year-old man with idiopathic pulmonary fibrosis (IPF)

mksap
Conditions
June 16, 2018
Share
Tweet
Share

Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.

A 58-year-old man is evaluated in follow-up for idiopathic pulmonary fibrosis (IPF), which was diagnosed 2 years ago. He has cough and shortness of breath and now requires supplemental oxygen at rest. Previous evaluations have not identified any cause for his symptoms other than progressive IPF. He has participated in pulmonary rehabilitation and continues in a maintenance program. He is a lifelong nonsmoker. His medical history is otherwise unremarkable, and he takes no medications.

On physical examination, the patient is afebrile, blood pressure is normal, pulse rate is 96/min, and respiration rate is 26/min; BMI is 27. Oxygen saturation is 92% breathing 4 L of oxygen by nasal cannula. Pulmonary examination reveals inspiratory crackles at the bases bilaterally.

Results of a 6-minute walk test are 335 meters (1100 feet) (declined from 457 meters [1500 feet] 6 months ago).

Which of the following is the most appropriate management?

A. Azathioprine
B. Daily prednisone
C. Etanercept
D. Lung transplantation

MKSAP Answer and Critique

The correct answer is D: Lung transplantation.

The most appropriate management is referral to a lung transplantation program. Individuals considered for lung transplantation are most often at high risk of death within 2 years due to respiratory failure and also have a high likelihood of long-term survival following the procedure. This patient with idiopathic pulmonary fibrosis (IPF) has a significant oxygen requirement at rest in addition to a documented decline in his 6-minute walk distance. Both of these factors substantially increase his risk for the development of respiratory failure. Furthermore, he has no history of comorbidities that would limit posttransplant survival, and he continues to actively participate in pulmonary rehabilitation. Lung transplantation remains the only intervention with a clear survival benefit for select patients with IPF.

Medical options for treatment of IPF are limited. The immunosuppressant azathioprine, given along with prednisone and N-acetylcysteine, has been studied in patients with IPF. However, this combination therapy was associated with increased mortality and adverse effects.

Therefore, azathioprine is not recommended for use in patients with IPF. In related studies, N-acetylcysteine used as single-agent therapy in IPF showed no benefit over placebo; thus, N-acetylcysteine is also no longer considered of value for treatment of IPF.

Although there is some debate as to the benefit of glucocorticoids in the treatment of patients with an acute exacerbation of IPF, there is no benefit to either short- or long-course prednisone in patients with IPF without an exacerbation. IPF is a disease with ongoing fibrosis but with limited inflammation. Consequently, glucocorticoids do little to affect the progressive fibrosis, and their many associated side effects only place the patient at increased risk of complications.

Treatment with tumor necrosis factor-α (TNF-α) inhibitors has been proposed as a method for decreasing the progressive pulmonary fibrosis associated with IPF. However, a trial of the TNF-α inhibitor etanercept failed to show benefit, and its use is not recommended in IPF.

Two new medical therapies have recently been approved for treatment of IPF. These are nintedanib, a tyrosine kinase inhibitor that moderates production of fibrogenic growth factors, and pirfenidone, whose mechanism is unclear but also modulates production of fibrosis. Both agents slow the decline in pulmonary function tests but do not affect quality of life and are not curative. The effect of these agents on disease progression appears to be very similar. To date, these agents have not been studied extensively in patients with acute exacerbation of IPF or severely advanced IPF. Pulmonary subspecialty assessment to confirm IPF and assess risk/benefit for the use of these drugs in selected patients is recommended. Consideration of participation in clinical trials for patients with this progressive disorder remains important for the development of future, more effective, medical therapies.

ADVERTISEMENT

Key Point

  • Patients with idiopathic pulmonary fibrosis who have a high risk for the development of respiratory failure and a high likelihood of long-term posttransplant survival should be referred to a lung transplantation program, and about treating the “worried well.”

This content is excerpted from MKSAP 17 with permission from the American College of Physicians (ACP). Use is restricted in the same manner as that defined in the MKSAP 16 Digital license agreement. This material should never be used as a substitute for clinical judgment and does not represent an official position of ACP. All content is licensed to KevinMD.com on an “AS IS” basis without any warranty of any nature. The publisher, ACP, shall not be liable for any damage or loss of any kind arising out of or resulting from use of content, regardless of whether such liability is based in tort, contract or otherwise.

Prev

3 ways to cut years off your medical school loan repayment period

June 15, 2018 Kevin 0
…
Next

The next time you see a medical student, give support

June 16, 2018 Kevin 2
…

Tagged as: Pulmonology

Post navigation

< Previous Post
3 ways to cut years off your medical school loan repayment period
Next Post >
The next time you see a medical student, give support

ADVERTISEMENT

More by mksap

  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 26-year-old man with back pain

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 36-year-old man with abdominal cramping, diarrhea, malaise, and nausea

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 52-year-old woman with osteoarthritis of the right hip

    mksap

Related Posts

  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 35-year-old woman with constipation

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 60-year-old woman with persistent constipation

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 45-year-old woman with type 2 diabetes mellitus

    mksap

More in Conditions

  • Why medicine must stop worshipping burnout and start valuing humanity

    Sarah White, APRN
  • Why perinatal mental health is the top cause of maternal death in the U.S.

    Sheila Noon
  • A world without vaccines: What history teaches us about public health

    Drew Remignanti, MD, MPH
  • Unraveling the mystery behind one of the most dangerous pregnancy complications: preeclampsia

    Thomas McElrath, MD, PhD and Kara Rood, MD
  • How community paramedicine impacts Indigenous elders

    Noah Weinberg
  • Pain is more than physical: the story your body is trying to tell

    Katie Hatt, DO
  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How community paramedicine impacts Indigenous elders

      Noah Weinberg | Conditions
    • Addressing U.S. vaccine inequities in vulnerable communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • How to speak the language of leadership to improve doctor wellness [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • How medical culture hides burnout in plain sight

      Marco Benítez | Conditions
  • Recent Posts

    • Addressing U.S. vaccine inequities in vulnerable communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why Canada is losing its skilled immigrant doctors

      Olumuyiwa Bamgbade, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Would The Pitts’ Dr. Robby Robinavitch welcome a new colleague? Yes. Especially if their initials were AI.

      Gabe Jones, MBA | Tech
    • Why medicine must stop worshipping burnout and start valuing humanity

      Sarah White, APRN | Conditions
    • Why screening for diseases you might have can backfire

      Andy Lazris, MD and Alan Roth, DO | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How community paramedicine impacts Indigenous elders

      Noah Weinberg | Conditions
    • Addressing U.S. vaccine inequities in vulnerable communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • How to speak the language of leadership to improve doctor wellness [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • How medical culture hides burnout in plain sight

      Marco Benítez | Conditions
  • Recent Posts

    • Addressing U.S. vaccine inequities in vulnerable communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why Canada is losing its skilled immigrant doctors

      Olumuyiwa Bamgbade, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Would The Pitts’ Dr. Robby Robinavitch welcome a new colleague? Yes. Especially if their initials were AI.

      Gabe Jones, MBA | Tech
    • Why medicine must stop worshipping burnout and start valuing humanity

      Sarah White, APRN | Conditions
    • Why screening for diseases you might have can backfire

      Andy Lazris, MD and Alan Roth, DO | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...